Tardive Dyskinesia Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rise in the Prevalence of Psychotic or Neurological Disorders
   3. Market Restraints
      1. Limited Awareness and Underdiagnosis
      2. Adverse Effects of Current Treatments
   4. Market Opportunities
      1. Increase in the Demand for Disease-Specific Novel Treatment
   5. Market Trends
      1. Increasing Adoption of Precision Medicine
      2. Expansion of Non-pharmacological Interventions
5. MARKET SEGMENTATION
   1. By Treatment
      1. Medication
      2. Surgery
   2. By Drugs
      1. Approved Drugs
      2. Off-label Drugs
   3. By Route of Administration
      1. Oral
      2. Injectable
   4. By End- Users
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   5. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Others
2. By Key Geographic Regions
   1. North America
      1. United States
      2. Canada
      3. Mexico
   2. Europe
      1. Germany
      2. United Kingdom
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. Asia Pacific
      1. China
      2. Japan
      3. India
      4. Australia
      5. South Korea
      6. Rest of Asia Pacific
   4. Middle East and Africa
      1. GCC
      2. South Africa
      3. Rest of Middle East and Africa
   5. South America
      1. Brazil
      2. Argentina
      3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Amgen Inc
      2. AbbVie Inc
      3. Bionpharma
      4. Bausch Health
      5. Bayer AG
      6. Baxter
      7. Dr. Reddy’s Laboratories Ltd
      8. GlaxoSmithKline Plc.
      9. Hetero
      10. Johnson & Johnson Services, Inc.
      11. Lupin Pharmaceuticals Inc.
      12. Lilly
      13. Merck KGaA
      14. Medicure Inc
      15. Novartis AG
      16. Neurocrine Biosciences, Inc
      17. Mylan N.V
      18. Pfizer Inc
      19. Sun Pharmaceutical Industries Ltd
      20. Sanofi
      21. Teva Pharmaceutical Industries Ltd
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Tardive Dyskinesiamarket?

The global market of Tardive Dyskinesia is projected to reach USD 8.74Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Tardive Dyskinesiamarket?

The global Tardive Dyskinesia market has an estimated annual growth rate of 9.3%. 

Q.3. What are the recent trends of Tardive Dyskinesiamarket?

Increasing adoption of precision medicine and expansion of non-pharmacological interventions are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Tardive Dyskinesia?

The major companies profiled in this report include Amgen Inc, AbbVie Inc, Bionpharma, Bausch Health, Bayer AG, Baxter, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Plc., Hetero, Johnson & Johnson Services, Inc., Lupin Pharmaceuticals Inc., Lilly, Merck KGaA, Medicure Inc, Novartis AG, Neurocrine Biosciences, Inc, Mylan N.V, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi, Teva Pharmaceutical Industries Ltd, among others.

Q.5. Which region is estimated to held highest CAGR inTardive Dyskinesiamarket?

North America is estimated to hold biggest share in the market for Tardive Dyskinesia.